# A Study to Assess the Amount of Drug Levels in Blood and Safety of AZD5718 Formulations in Healthy Volunteers

> **NCT04210388** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 12 (actual)

## Conditions studied

- Coronary Artery Disease (CAD)

## Interventions

- **DRUG:** AZD5718 tablet, Formulation A
- **DRUG:** AZD5718 tablet, Formulation B
- **DRUG:** AZD5718 tablet, Formulation C
- **DRUG:** AZD5718 tablet, Formulation D
- **DRUG:** AZD5718 film-coated tablet, Reference treatment

## Key facts

- **NCT ID:** NCT04210388
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-14
- **Primary completion:** 2020-03-09
- **Final completion:** 2020-03-09
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2020-03-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04210388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04210388, "A Study to Assess the Amount of Drug Levels in Blood and Safety of AZD5718 Formulations in Healthy Volunteers". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04210388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*